VIASAT INC Income Taxes Disclosure
Note 10 — Income Taxes
The components of income (loss) before income taxes by jurisdiction were as follows:
|
|
Fiscal Years Ended |
|
|||||||||
|
|
March 31, |
|
|
March 31, |
|
|
March 31, |
|
|||
|
|
(In thousands) |
|
|||||||||
United States |
|
$ |
(161,596 |
) |
|
$ |
(329,591 |
) |
|
$ |
(859,006 |
) |
Foreign |
|
|
266,397 |
|
|
|
(215,703 |
) |
|
|
(334,940 |
) |
|
|
$ |
104,801 |
|
|
$ |
(545,294 |
) |
|
$ |
(1,193,946 |
) |
The (provision for) benefit from income taxes included the following:
|
|
Fiscal Years Ended |
|
|||||||||
|
|
March 31, |
|
|
March 31, |
|
|
March 31, |
|
|||
|
|
(In thousands) |
|
|||||||||
Current tax (provision) benefit: |
|
|
|
|
|
|
|
|
|
|||
Federal |
|
$ |
(6,499 |
) |
|
$ |
(28,247 |
) |
|
$ |
(12,128 |
) |
State |
|
|
(7,050 |
) |
|
|
(2,661 |
) |
|
|
(1,010 |
) |
Foreign |
|
|
(56,735 |
) |
|
|
(117,042 |
) |
|
|
(27,028 |
) |
|
|
|
(70,284 |
) |
|
|
(147,950 |
) |
|
|
(40,166 |
) |
Deferred tax (provision) benefit: |
|
|
|
|
|
|
|
|
|
|||
Federal |
|
|
(28,380 |
) |
|
|
16,770 |
|
|
|
74,404 |
|
State |
|
|
(937 |
) |
|
|
(102 |
) |
|
|
5,166 |
|
Foreign |
|
|
(16,622 |
) |
|
|
132,223 |
|
|
|
100,070 |
|
|
|
|
(45,939 |
) |
|
|
148,891 |
|
|
|
179,640 |
|
Total (provision for) benefit from income taxes |
|
$ |
(116,223 |
) |
|
$ |
941 |
|
|
$ |
139,474 |
|
Significant components of the Company’s net deferred tax assets were as follows:
|
|
As of |
|
|||||
|
|
March 31, |
|
|
March 31, |
|
||
|
|
(In thousands) |
|
|||||
Deferred tax assets: |
|
|
|
|
|
|
||
Net operating loss carryforwards |
|
$ |
388,035 |
|
|
$ |
252,589 |
|
Tax credit carryforwards |
|
|
178,366 |
|
|
|
159,806 |
|
Capitalized research and development costs |
|
|
65,417 |
|
|
|
136,191 |
|
Operating lease liabilities |
|
|
99,134 |
|
|
|
99,877 |
|
Interest carryforwards |
|
|
34,260 |
|
|
|
105,182 |
|
Other |
|
|
182,575 |
|
|
|
198,071 |
|
Valuation allowance |
|
|
(434,983 |
) |
|
|
(430,501 |
) |
Total deferred tax assets |
|
|
512,804 |
|
|
|
521,215 |
|
Deferred tax liabilities: |
|
|
|
|
|
|
||
Intangible assets |
|
|
(533,515 |
) |
|
|
(576,599 |
) |
Property, equipment and satellites |
|
|
(776,440 |
) |
|
|
(689,880 |
) |
Operating lease assets |
|
|
(91,280 |
) |
|
|
(88,083 |
) |
Other |
|
|
(59,720 |
) |
|
|
(75,918 |
) |
Total deferred tax liabilities |
|
|
(1,460,955 |
) |
|
|
(1,430,480 |
) |
Net deferred tax assets (liabilities) |
|
$ |
(948,151 |
) |
|
$ |
(909,265 |
) |
A reconciliation of the benefit from (provision for) income taxes to the amount computed by applying the statutory federal income tax rate to income (loss) before income taxes for the fiscal year ended March 31, 2026 is as follows:
|
|
Fiscal Year Ended |
|
|||||
|
|
March 31, 2026 |
|
|||||
|
|
Dollar |
|
|
Percentage |
|
||
|
|
(In thousands) |
|
|
|
|
||
U.S. federal statutory tax rate |
|
$ |
(22,008 |
) |
|
|
21 |
% |
State and local income taxes, net of federal income tax effect (1) |
|
|
(6,532 |
) |
|
6 |
|
|
Foreign tax effects |
|
|
|
|
|
|
||
United Kingdom |
|
|
|
|
|
|
||
Statutory tax rate difference between United Kingdom and United States |
|
|
(5,053 |
) |
|
|
5 |
|
Interest on overpaid taxes, net of income tax effect |
|
|
5,146 |
|
|
|
(5 |
) |
Other |
|
|
5,635 |
|
|
|
(5 |
) |
Canada |
|
|
|
|
|
|
||
Statutory tax rate difference between Canada and United States |
|
|
10,226 |
|
|
|
(10 |
) |
Local provincial income taxes |
|
|
(20,332 |
) |
|
|
19 |
|
Capital gain partial exemption on sale of Navarino UK |
|
|
12,605 |
|
|
|
(12 |
) |
Tax audit adjustments |
|
|
(5,619 |
) |
|
|
5 |
|
Withholding taxes |
|
|
(8,993 |
) |
|
|
9 |
|
Other |
|
|
(3,050 |
) |
|
|
3 |
|
Other foreign jurisdictions |
|
|
(20,969 |
) |
|
|
20 |
|
Effect of changes in tax laws or rates enacted in the current period |
|
|
(10,061 |
) |
|
|
10 |
|
Effect of cross-border tax laws |
|
|
|
|
|
|
||
Global intangible low-taxed income (GILTI) |
|
|
(43,061 |
) |
|
|
41 |
|
Subpart F income |
|
|
(45,418 |
) |
|
|
43 |
|
Inclusion of foreign disregarded entities |
|
|
(3,451 |
) |
|
|
3 |
|
Other |
|
|
1,324 |
|
|
|
(1 |
) |
Tax credits |
|
|
|
|
|
|
||
Research and development tax credits |
|
|
10,558 |
|
|
|
(10 |
) |
Changes in valuation allowances |
|
|
48,628 |
|
|
|
(46 |
) |
Nontaxable or nondeductible Items |
|
|
|
|
|
|
||
Non-deductible compensation |
|
|
(3,594 |
) |
|
|
3 |
|
Other |
|
|
(8,507 |
) |
|
|
8 |
|
Changes in prior period worldwide unrecognized tax benefits |
|
|
3,029 |
|
|
|
(3 |
) |
Other adjustments |
|
|
|
|
|
|
||
Unremitted subsidiary gains |
|
|
(4,380 |
) |
|
|
4 |
|
Other |
|
|
(2,346 |
) |
|
|
2 |
|
Total |
|
$ |
(116,223 |
) |
|
|
111 |
% |
(1) State taxes in Virginia and Maryland made up the majority (greater than 50 percent) of the tax effect in this category.
A reconciliation of the benefit from (provision for) income taxes to the amount computed by applying the statutory federal income tax rate to income (loss) before income taxes for the fiscal years ended March 31, 2025 and 2024 is as follows:
|
|
Fiscal Years Ended |
|
|||||
|
|
March 31, |
|
|
March 31, |
|
||
|
|
(In thousands) |
|
|||||
Tax (provision) benefit at federal statutory rate |
|
$ |
114,512 |
|
|
$ |
250,728 |
|
State tax provision, net of federal benefit |
|
|
8,908 |
|
|
|
28,621 |
|
Tax credits |
|
|
16,004 |
|
|
|
28,574 |
|
Change in federal valuation allowances |
|
|
(49,566 |
) |
|
|
(105,968 |
) |
Change in state valuation allowances |
|
|
(10,880 |
) |
|
|
(27,251 |
) |
Non-deductible compensation |
|
|
(2,459 |
) |
|
|
(5,240 |
) |
Non-deductible transaction costs |
|
|
(40 |
) |
|
|
(18,911 |
) |
Non-deductible meals and entertainment |
|
|
(1,112 |
) |
|
|
(1,077 |
) |
Stock-based compensation |
|
|
(12,932 |
) |
|
|
(12,182 |
) |
Change in state effective tax rate |
|
|
(452 |
) |
|
|
292 |
|
Base Erosion and Anti-Abuse Tax (BEAT) |
|
|
(30,448 |
) |
|
— |
|
|
Foreign effective tax rate differential, net of valuation allowance |
|
|
(9,185 |
) |
|
|
6,199 |
|
Unremitted subsidiary gains |
|
|
(7,043 |
) |
|
|
(1,586 |
) |
Withholding taxes |
|
|
(6,852 |
) |
|
|
(4,981 |
) |
Other |
|
|
(7,514 |
) |
|
|
2,256 |
|
Total (provision for) benefit from income taxes |
|
$ |
941 |
|
|
$ |
139,474 |
|
As of March 31, 2026, the Company had federal and state R&D tax credit carryforwards of $157.3 million and $217.6 million, respectively, which begin to expire in fiscal year 2040 and fiscal year 2027, respectively. As of March 31, 2026, the Company had federal and state net operating loss carryforwards of $1,296.2 million and $673.0 million, respectively, which begin to expire in fiscal year 2029 and fiscal year 2027, respectively. However, the majority of the federal net operating loss carryforwards do not expire.
As of March 31, 2026, the Company's deferred tax assets for net operating loss carryforwards included $64.2 million of UK capital loss carryforwards, which can only be offset against future UK capital gains. A full valuation allowance has been established against the capital loss carryforwards, as no capital gains are expected. With limited exceptions, the Company's foreign net operating loss and interest carryforwards do not expire. However, certain transactions or material changes to the Company's global financing arrangements could limit the Company's right to use its foreign deferred tax assets and make netting against deferred tax liabilities inappropriate, resulting in an increase to the valuation allowance and income tax expense.
In accordance with ASC 740, net deferred tax assets are reduced by a valuation allowance if, based on all the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Future realization of existing deferred tax assets ultimately depends on future profitability and the existence of sufficient taxable income of appropriate character (for example, ordinary income versus capital gains) within the carryforward period available under tax law. In the event that the Company’s estimate of taxable income is less than that required to utilize the full amount of any deferred tax asset, a valuation allowance is established, which would cause a decrease to income in the period such determination is made. A valuation allowance of $435.0 million at March 31, 2026 and $430.5 million at March 31, 2025 has been established relating to carryforwards of federal, state and foreign net operating losses, federal and state R&D tax credits, and foreign tax credits, and to other federal and state net deferred tax assets for cumulative timing differences that, based on management’s estimate of future taxable income attributable to such jurisdictions and generation of additional research credits, are considered more likely than not to expire unused.
In July 2025, the One Big Beautiful Bill Act (OBBBA) was enacted in the U.S. The OBBBA includes a broad range of material business tax reforms, such as 100% bonus depreciation, expensing of U.S.-based research and development, modification of the interest expense limitation, and modification of various U.S. international tax provisions. For fiscal year 2026, the tax law changes resulted in approximately $10.7 million of incremental non-cash tax expense to increase the Company’s U.S. valuation allowance due to material changes in the Company’s mix of gross deferred tax assets and liabilities. Additionally, the tax law changes decreased cash paid for income taxes in fiscal year 2026 associated with the Company's majority-owned subsidiary primarily due to the accelerated amortization of research and development expenses that were previously capitalized for tax purposes.
During the fourth quarter of fiscal year 2025, the Company released $10.3 million of valuation allowance previously recorded against U.S. deferred tax assets. The Company evaluated both the positive and negative evidence and released valuation allowance equal to the expected benefit from the deferred tax liabilities recorded for legacy Inmarsat U.S. entities in connection with a tax planning strategy to file a consolidated U.S. federal tax return.
During the second quarter of fiscal year 2024, in evaluating the Company’s ability to realize its U.S. net deferred tax assets, the Company considered all available positive and negative evidence, including but not limited to operating results, forecasted ranges of future taxable income, and its recent satellite anomalies. ASC 740 places more weight on the objectively verifiable evidence of current pre-tax losses and recent events than forecasts of future profitability. Therefore, the Company determined it is more likely than not that its U.S. net deferred tax assets will not be realized, excluding its deferred tax assets and liabilities related to the separate U.S. tax return filings of TrellisWare and the legacy Inmarsat entities. As a result, the Company’s tax benefit for fiscal year 2024 was reduced by a valuation allowance recorded against such U.S. deferred tax assets.
The following table summarizes the activity related to the Company’s unrecognized tax benefits:
|
|
As of |
|
|||||||||
|
|
March 31, |
|
|
March 31, |
|
|
March 31, |
|
|||
|
|
(In thousands) |
|
|||||||||
Balance, beginning of fiscal year |
|
$ |
188,186 |
|
|
$ |
185,595 |
|
|
$ |
129,738 |
|
Increase related to prior year tax positions |
|
|
1,200 |
|
|
|
1,571 |
|
|
|
2,728 |
|
Decrease related to prior year tax positions |
|
|
(265 |
) |
|
|
(253 |
) |
|
|
(190 |
) |
Increase related to current year tax positions |
|
|
49,117 |
|
|
|
14,017 |
|
|
|
15,608 |
|
Increase related to business combinations |
|
— |
|
|
— |
|
|
|
54,193 |
|
||
Expiration of the statute of limitations for the assessment of taxes |
|
|
(11,054 |
) |
|
|
(12,744 |
) |
|
|
(16,482 |
) |
Balance, end of fiscal year |
|
$ |
227,184 |
|
|
$ |
188,186 |
|
|
$ |
185,595 |
|
Of the total unrecognized tax benefits at March 31, 2026, $13.6 million would reduce the Company’s annual effective tax rate if recognized, based on the Company's valuation allowance position at March 31, 2026.
The Company’s policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. As of March 31, 2026 and 2025, the Company had accrued interest expense and penalties of approximately $9.0 million and $14.4 million, respectively. The Company recognized a tax benefit of $5.5 million for fiscal year 2026 and an insignificant amount for each of fiscal years 2025 and 2024 for reductions of interest expense and penalties in income tax expense. In addition, as of March 31, 2026 and 2025, the Company had accrued interest income of approximately $7.1 million and an insignificant amount, respectively. The Company recognized a tax benefit of $4.6 million for fiscal year 2026 and an insignificant amount for each of fiscal years 2025 and 2024 for interest income in income tax expense.
The Company is subject to periodic audits by domestic and foreign tax authorities. By statute, the Company’s U.S. federal and state income tax returns are subject to examination by the tax authorities for fiscal years 2023 and thereafter. Additionally, net operating loss and R&D tax credit carryovers that were generated in prior years may also be subject to examination. The Company’s U.S. federal income tax return for fiscal year 2024 is currently under examination by the Internal Revenue Service. Calendar years 2014 and thereafter remain open in Norway for certain entities currently under examination. Calendar years 2018 and thereafter remain open in Canada for certain entities currently under examination. With few exceptions, fiscal years 2022 and thereafter remain open by statute to examination by other foreign tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and its accruals for tax liabilities are adequate based on an assessment of many factors, including experience and interpretations.
The income taxes paid, net of refunds received, for the fiscal year ended March 31, 2026 was as follows:
|
|
Fiscal Year Ended |
|||
|
|
March 31, 2026 |
|||
|
|
(In thousands) |
|
|
|
Federal |
|
$ |
10,103 |
|
|
State |
|
|
1,472 |
|
|
Foreign |
|
|
|
|
|
United Kingdom |
|
|
49,443 |
|
|
Brazil |
|
|
5,928 |
|
|
Other foreign jurisdictions |
|
|
13,755 |
|
|
Total cash paid for income taxes, net |
|
$ |
80,701 |
|
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2026 | May 29, 2026 | Showing above |
| 2025 | May 27, 2025 | |
| 2024 | May 29, 2024 | |
| 2023 | May 22, 2023 | |
| 2022 | May 31, 2022 | |
| 2021 | May 28, 2021 | |
| 2020 | May 29, 2020 | |
| 2019 | May 29, 2019 | |
| 2018 | May 30, 2018 | |
| 2017 | May 25, 2017 | |
| 2016 | May 26, 2016 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.